Abstracts Archive - Page 2352 of 2607 - ACR Meeting Abstracts

Abstract Number: 1204 • 2013 ACR/ARHP Annual Meeting
Model-Based Pharmacokinetics Of Canakinumab and Pharmacodynamics Of IL-1Beta Binding In Cryopyrin Associated Periodic Syndromes, a Step Towards Personalized Medicine
Aurélie Gautier¹, Phil Lowe¹, Andrej Skerjanec¹, Phil McKernan¹, Wenping Wang² and Olivier Luttringer¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS), comprises of extremely rare, inherited auto-inflammatory diseases, including the mildest form familial cold auto-inflammatory syndrome (FCAS), the more severe Muckle-Wells…
Abstract Number: 1205 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort.A Single Center Experience
Virginia Moreira-Navarrete¹, Francisco Javier Toyos Saenz de Miera², Carmen Vargas Lebrón³ and F. Navarro Sarabia⁴, ¹Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ²Hospital Virgen de la Macarena, Sevilla, Spain, ³Hospital Virgen Macarena, SEVILLA, Spain, ⁴Rheumatologist Service, Hospital Universitario Virgen Macarena, Sevilla, Spain
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) comprises a group of rare, but severe, autoinflammatory diseases, characterized by urticaria, periodic fever, central nervous system inflammation, arthropathy, and…
Abstract Number: 1206 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment Regimens In CAPS Patients
Ferdinand Hofer¹, Theresa Endres¹, Birgit Kortus-Goetze², Norbert Blank³, Elisabeth Weissbarth-Riedel⁴, Catharina Schuetz⁵, Tilmann Kallinich⁶, Karoline Krause⁷, Christoph Rietschel⁸, Gerd Horneff⁹ and Jasmin B. Kuemmerle-Deschner¹⁰, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²Klinik für Innere Medizin, Klinikum der Philipps-Universität Marburg, Marburg, Germany, ³University of Heidelberg, Heidelberg, Germany, ⁴Kinderrheumatologische Ambulanz, Universitätsklinikum Eppendorf, Hamburg, Germany, ⁵Klinik für Kinder und Jugendmedizin, Universitätsklinikum Ulm, Ulm, Germany, ⁶Charite, University Medicine Berlin, Berlin, Germany, ⁷Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁸Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany, ⁹Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and approved for the treatment of CAPS in many countries including Europe and the…
Abstract Number: 1207 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Sedat Yilmaz¹, Muhammet Cinar², Ismail Simsek¹, Hakan Erdem³ and Salih Pay³, ¹Gulhane School of Medicine, Ankara, Turkey, ²Rheumatology, Gulhane School of Medicine, Ankara, Turkey, ³Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey
Background/Purpose: The most frequent underlying diseases responsible for AA amyloidosis worldwide are rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis, while familial Mediterranean fever (FMF)…
Abstract Number: 1208 • 2013 ACR/ARHP Annual Meeting
Canakinumab In Patients With FMF
Serdal Ugurlu¹, Emire Seyahi¹, Gulen Hatemi², Ayse Hacioglu² and Huri Ozdogan², ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In a recent pilot study, it was reported that Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant…
Abstract Number: 1209 • 2013 ACR/ARHP Annual Meeting
Starting Time Of Inflammatory Attacks In Patients With Familial Mediterranean Fever
Feyza Berktas¹, Nilufer Alpay Kanitez¹, Bahtiyar Toz¹, Oguz Kaan Bakkaloglu¹, Burak Erer² and Ahmet Gul¹, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF), the most common form of the hereditary autoinflammatory diseases, is characterized by recurrent self-limiting attacks of fever and/or serositis accompanied…
Abstract Number: 1210 • 2013 ACR/ARHP Annual Meeting
Epicardial Adipose Tissue and Atherosclerosis In Patients With Familial Mediterranean Fever
Adem Kucuk¹, Yalcin Solak², Hakan Akilli³, Oguzhan Yildirim³, Ibrahim Guler⁴, Ramazan Ucar⁵, Alpay Aribas³, Orhan Ozbek⁶, Mehmet Kayrak³ and Recep Tunc¹, ¹Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ²Karaman State Hospital, Division of Nephrology, Karaman, Turkey, ³Necmettin Erbakan University, Division of Cardiology, Konya, Turkey, ⁴Konya Research and Education Hospital, Division of Radiology, Konya, Turkey, ⁵Konya Education and Research Hospital, Department ofInternal Medicine, Konya, Turkey, ⁶Necmettin Erbakan University, Division of Radiology, Konya, Turkey
Background/Purpose : Familial Mediterranean Fever (FMF) is a chronic autosomal recessive hereditary disease characterized by episodic attacks of fever and inflammation of serosal and synovial…
Abstract Number: 1211 • 2013 ACR/ARHP Annual Meeting
Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever?
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Familial Mediterranean fever (FMF) is traditionally regarded as an autosomal recessive disease characterized by periodic fever, serositis, erysipelas-like erythema and good response to colchicine. The…
Abstract Number: 1212 • 2013 ACR/ARHP Annual Meeting
Are Different Disease Subtypes With Distinct Clinical Expression Present In Familial Mediterranean Fever: Results Of a Cluster Analysis
Servet Akar¹, Timucin Kasifoglu², Dilek Solmaz¹, Sule Yasar Bilge², Ismail Sari¹ and Mehmet Tunca³, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disorder characterized by self limited attacks of fever and serositis. The disease expression may be different in…
Abstract Number: 1213 • 2013 ACR/ARHP Annual Meeting
Low-Penetrance NLRP3-Variants
Theresa Endres¹, Ferdinand Hofer¹, Raphaela T. Goldbach-Mansky², Hal M. Hoffman³, Norbert Blank⁴, Karoline Krause⁵, Christoph Rietschel⁶, Gerd Horneff⁷, Peter Lohse⁸ and Jasmin B. Kuemmerle-Deschner⁹, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁶Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany, ⁷Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁸Institut für Laboratoriumsmedizin und Humangenetik, Singen, Germany, ⁹University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) presents as rare, autosomal dominant disease spectrum, due to mutations in the NLRP3-gene which lead to excessive interleukin-1 (IL-1) release.…
Abstract Number: 1174 • 2013 ACR/ARHP Annual Meeting
Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
Nicola Dalbeth¹, Peggy Chen², Marie White³, Gregory Gamble⁴, Caran Barratt-Boyes², Peter J. Gow⁵ and Brandon Orr-Walker², ¹Medicine, University of Auckland, Auckland, New Zealand, ²Counties Manukau District Health Board, Auckland, New Zealand, ³CCRep, Auckland, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Rheumatology Dept, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: Weight loss leads to reduced serum urate (SU) in people with obesity. However, the clinical relevance of such reductions in SU are unknown. This…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 1176 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
Anthony J. Bleyer¹, David E. Wright² and Alan Glicklich³, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Savient Pharmaceuticals, Inc., San Diego, CA, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Among the estimated 8.3 million adults in the US with gout, approximately 40% have coexistent chronic kidney disease (CKD).1,2 Further, the presence of gout…
Abstract Number: 1177 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Prashanth Sunkureddi¹, Edith Toth², Jacques P. Brown³, Rüdiger Möricke⁴, Jan Michael Nebesky⁵, Gerhard Krammer⁵, Aiyang Tao⁶, Markus John⁵ and Alan Kivitz⁷, ¹Rheumatology, Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Canakinumab (CAN), a selective, fully human, monoclonal anti-IL-1β antibody has demonstrated long-term benefits in gouty arthritis (GA) patients (pts) by targeting the inflammatory pathway…
Abstract Number: 1178 • 2013 ACR/ARHP Annual Meeting
Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
Kenneth G. Saag¹, Michael A. Becker², Andrew Whelton³, Patricia A. MacDonald⁴, Yun Zhou⁵ and Lhanoo Gunawardhana⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Chicago, Chicago, IL, ³The Johns Hopkins University and Universal Clinical Research Center, Inc., Baltimore, MD, ⁴Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ⁵Takeda Global Research & Development Center, Inc., Deerfield, IL
Background/Purpose: Up to 20% of patients with hyperuricemia (serum urate [sUA] >6.8 mg/dL) and gout have moderate-to-severe renal impairment. Higher sUA (>8.5 mg/dL) may increase the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].